The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And the argument has been that rapamycin itself has cancer cell autonomous effects. Independent of the immune modulation problem. So you're presumably getting less immune surveillance because it's immunosuppressant, although, of course, that's not proven. But you're mitigating that by now directly targeting the cancer. And they've canceled each other out.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
And there actually has been some epidemiological data where people have compared cancer rates in transplant patients. Identical patients who are with and without rapamycin. FK506 versus rapamycin. And it's actually quite interesting because, as you know, immunosuppression in general is associated with higher cancer rates, right? The idea that you have less immune surveillance. That's not seeing rapamycin. So it is seen with FK506. It's not seen with rapamycin.
the reason Rap did not is because it itself has anti
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.